Navigation Links
Stipulation Of Dismissal Of Claims By Plaintiff Cornerstone Biopharma, Inc.
Date:7/11/2013

ESTERO, Fla., July 11, 2013 /PRNewswire/ -- On May 16, 2013, United States District Court for the Eastern District of North Carolina DISMISSED with prejudice all claims for copyright and patent infringement asserted by plaintiffs Cornerstone BioPharma, Inc. ("Cornerstone") and J-Med Pharmaceuticals, Inc. ("J-Med") against Vision Pharma, LLC ("Vision"), Sander Busman, Thomas DeStefano, and Michael McAloose.  The dismissal followed the decision of the United States Court of Appeals for the Federal Circuit, upholding the USPTO Board of Patent Appeals and Interferences' rejection of U.S. Patent No. 6,270,796, the sole patent asserted in the case. See In re J-Med Pharmaceuticals, Inc., No. 11-1415 (Fed. Cir.).  On January 11, 2013, the USPTO issued an Ex Parte Reexamination Certificate cancelling all claims of the '796 Patent.

"We were very confident from the absolute beginning that Vision, Thomas DeStefano, Michael McAloose and I would receive a most favorable outcome regarding Cornerstone and J-Med's case against us.  Although these results are especially pleasing, this decision should not have taken so long to happen," said Sander S. Busman, Founder, President & CEO, Vision Pharma. Vision Pharma was represented by Ben Pleune and David Alban of Alston & Bird, LLP. 

About Vision Pharma

Vision Pharma specializes in niche, generic pharmaceuticals with various delivery options and dosage forms.  The company provides quality products at competitive prices while improving the lives of those who take their medicines. The organization's customer service acts promptly to requests while continuously improving to fulfill each customer and patient need. Maintaining additional inventory ensures Vision's ability to provide increased service levels. The pipeline of generic pharmaceuticals planned to market continues to be a strong focus internally and with other pharmaceutical organizations, domestically and internationally. Valuable relationships that are built show true dedication to each partnering company. You can count on Vision Pharma to consider the patient's safety as a top priority when developing and manufacturing their items. To learn more, please visit www.visionpharma.com.

Media Relations Contact:
Sander S. Busman
Vision Pharma
Founder, President & CEO
sbusman@visionpharma.com

 

 


'/>"/>
SOURCE Vision Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Breckenridge Announces Dismissal of Various Lawsuits Against Macoven Pharmaceuticals in Return for Macovens Discontinuance of Certain Products
2. Medstrat Posts Documents Confirming Terms Of Dismissal Of Merges Lawsuit
3. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intuitive Surgical, Inc. - ISRG
4. Specialty pharmacy utilization management programs and 30-day supply claims may improve patient outcomes, reduce waste
5. Bloomberg BNA Publishes Sixth Edition of False Claims Act Treatise
6. FDA Publicly Challenged to Support Unsubstantiated Claims Regarding Electronic Cigarettes
7. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of MAP Pharmaceuticals, Inc. - MAPP
8. Argus Announces Next Generation Pharmacy Claims Processing Solution
9. American Association for Homecare Expects Medicare to Move Past its Deny-at-All-Costs Culture that Routinely Denies Claims for Power Wheelchairs
10. Abbott Sued for False Claims Related to its Blockbuster Drug TriCor
11. Star Scientific, Inc. Issues Statement in Response to Two Plaintiffs Purported Class Action Law Suits and Multiple Press Releases Issued by Plaintiffs Law Firms Trolling for New Clients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... 2017  As the specialty pharmacy industry and ... make the revolutionary shift from volume-based to value-based ... positive patient outcomes and shaping the future of ... away from clinical trials and toward data that ... drug therapy utilization in precise patient populations. Therigy ...
(Date:5/15/2017)... , May 15, 2017 Enterin Inc., a ... and developing novel compounds to treat Parkinson,s disease (PD), ... study is a Phase 1/2a randomized, controlled, multicenter study involving ... It will enroll 50 patients over a 9-to-12-month period. The ... in 10 patients with PD. Participating sites include ...
(Date:5/10/2017)... May 10, 2017 Global Health Intelligence ... Latin America , published its 2017 ranking of the ... based on extensive data analysis from GHI,s hospitals database ... database for the region. The GHI database covers 86% of ... more than 130 data points for each institution in key ...
Breaking Medicine Technology:
(Date:5/26/2017)... , ... May 26, 2017 , ... “When the Stars ... Home” is the creation of published author Laura Weigel Douglas, an avid reader who ... in a house that sometimes feels like Green Hills Adventure Camp. She couldn’t be ...
(Date:5/26/2017)... ... 2017 , ... Centennial-based BluSky Restoration Contractors announced that The ... Clays for Kids fundraiser, to be held Friday, Sept. 22, at Kiowa Creek ... of BluSky’s partnership with The Adoption Exchange, BluSky will also share sponsorship with ...
(Date:5/26/2017)... , ... May 26, 2017 , ... “Cactus Jack: Against ... on so many others. “Cactus Jack: Against All Odds” is the creation of ... Walter D. Hubbard is married to Jack Carlisle’s third child Jane. Walter. Walter ...
(Date:5/24/2017)... ... May 24, 2017 , ... Last month, representatives from ... employees, and town officials to celebrate the grand opening of the 87,000 square ... as part of its ongoing relationship with RWJBarnabas Health, New Jersey’s largest health ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Alan I. Benvenisty, MD is dual board ... He is known for his distinguished expertise and experience in the diagnosis and treatment ... training in treating renovascular disease and aortic aneurysm . He is known for ...
Breaking Medicine News(10 mins):